DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Emp-Activity: Empagliflozin Functional Capacity

Completed

Conditions: Heart Failure

Interventions: Drug: Empagliflozin

First Posted Date: 2022-04-28

Last Posted Date: 2024-12-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3451

Registration Number: NCT05350202

Locations: 🇧🇬
Dr. Petrova, Yambol, Bulgaria
🇧🇬
Dr. Toneva-Zhelaeva, Yambol, Bulgaria
🇨🇿
MUDr. Libor Nechvátal s.r.o., Brno, Czechia

and more 346 locations

A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809

First Posted Date: 2022-04-26

Last Posted Date: 2023-01-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT05347004

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1815368 formulation 1
Drug: Placebo
Drug: BI 1815368 formulation 2

First Posted Date: 2022-04-20

Last Posted Date: 2022-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT05337592

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: BI 770371
Drug: ezabenlimab

First Posted Date: 2022-04-14

Last Posted Date: 2025-04-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT05327946

Locations: 🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇨🇦
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada

and more 2 locations

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BI 1015550
Drug: Placebo

First Posted Date: 2022-04-11

Last Posted Date: 2025-03-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1177

Registration Number: NCT05321069

Locations: 🇺🇸
Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States
🇺🇸
Weill Cornell Medicine-New York-59955, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 331 locations

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Phase 3

Completed

Conditions: Lung Diseases, Interstitial

Interventions: Drug: BI 1015550
Drug: Placebo

First Posted Date: 2022-04-11

Last Posted Date: 2025-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1178

Registration Number: NCT05321082

Locations: 🇫🇷
HOP Louis Pradel, Bron, France
🇫🇷
HOP CHU Caen, Caen, France
🇫🇷
HOP François Mitterrand, Dijon, France

and more 400 locations

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Phase 1

Completed

Conditions: Healthy
Liver Diseases
Obesity

Interventions: Drug: BI 456906

First Posted Date: 2022-03-25

Last Posted Date: 2024-08-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 82

Registration Number: NCT05296733

Locations: 🇸🇰
SUMMIT CLINICAL RESEARCH, s.r.o., Bratislava, Slovakia
🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

and more 9 locations

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

Phase 3

Active, not recruiting

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib (Ofev®)

First Posted Date: 2022-03-18

Last Posted Date: 2025-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT05285982

Locations: 🇳🇴
Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway
🇵🇱
Independent Public Teaching Children's Hospital, Warsaw, Poland
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

and more 24 locations

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Phase 2

Terminated

Conditions: Liver Diseases
Hypertension, Portal

Interventions: Drug: Avenciguat
Drug: Empagliflozin

First Posted Date: 2022-03-16

Last Posted Date: 2025-04-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 90

Registration Number: NCT05282121

Locations: 🇫🇷
HOP Beaujon, Clichy, France
🇫🇷
HOP Rangueil, Toulouse, France
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany

and more 28 locations

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Not Applicable

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Zentiva®
Drug: Placebo

First Posted Date: 2022-03-14

Last Posted Date: 2024-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT05278104

Locations: 🇩🇪
Universitätsklinikum Aachen, AöR, Aachen, Germany
🇩🇪
Rheinhessen-Fachklinik Alzey, Alzey, Germany
🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy